èšåºæ®µéã®ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Advaxis, Inc. ã¯ãç±³åœã§ç¬èªã®ãªã¹ããªã¢ ã¢ããµã€ãã²ãã¹ (Lm) æè¡æåéé補åã®çºèŠãéçºãããã³åååã«æ³šåããŠããŸããå瀟ã¯ã転移æ§åç«è
ºããã®æ²»çãç®çãšãã第 2 çžèšåºè©Šéšäžã® ADXS-PSAãéå°çްèèºããã®æ²»çãç®çãšãã第 1/2 çžèšåºè©Šéšäžã® ADXS-503ãããã³åç«è
ºããã®æ²»çãç®çãšãã ADXS-504 ãéçºããŠããŸãããŸããçŸæ£ã«çŠç¹ãçµã£ããããã¹ããã/æ¢è£œã®æ°æåæåæ§çæ³ãããããããŒããŠã€ã«ã¹é¢é£ãããããã³åç«è
ºããã®é åã§ãLm ãã¯ãããžãŒå
ç«çæ³ã®èšåºè©Šéšãè¡ã£ãŠããŸããå瀟ã¯ãMerck & Co., Inc.ãOS Therapies, LLCãAratana Therapeutics Inc.ãBiocon LimitedãGlobal BioPharma Inc.ãKnight Therapeutics Inc ãªã©ãšååé¢ä¿ããã³ããŒãããŒã·ãããçµãã§ããŸãã Advaxis, Inc. 㯠2002 幎ã«èšç«ããããã¥ãŒãžã£ãŒãžãŒå·ã¢ã³ãã¹ãžã£ã³ã¯ã·ã§ã³ã«æ¬ç€Ÿã眮ããŠããŸãã